Пиразинамид 500 мг таблетки

Ülke: Kırgızistan

Dil: Rusça

Kaynak: Правительства Кыргызской Республики (Департамент лекарственного обеспечения и медицинской техники)

Aktif bileşen:

Пиразинамид

Mevcut itibaren:

АО "Фармасинтез"

ATC kodu:

J04AK01

INN (International Adı):

Pyrazinamide

Doz:

500 мг

Farmasötik formu:

таблетки

Paketteki üniteler:

№100

Reçete türü:

по рецепту

Tarafından üretildi:

АО "Фармасинтез" (Россия)

Terapötik alanı:

Противотуберкулезное средство

Ürün özeti:

ПЖВЛС: нет

Yetkilendirme tarihi:

2017-01-18

Ürün özellikleri

Aen
o6ecueqenu
MnH
per{top
HOro
v
HHg
[IKH
20
IIHCTPyK
I\L|fl,IIo
MEAIIqI,IHCKOMy
IIPIIMEHEHIIIO
JIEKAPCTBEHHOIO
CPENCTBA
TIIIPA3IIHAMI{A
Perucrpaullonnslfr
HoMeP
v
(
Topronoe
Ha3BaHIre
fiperapara
:
flupa:uuartu4
MexayHapoAHoe
HenaTeHToBaHHoe
Ha3BaH[Ie
[peflapaTa:
flupa:uuauzA
JlercapcrneHHafl
Qopnaa
: ra6lerxlt
Cocrae
Ha
oAHY
ra6.nerrcY:
f
e
[tcmeynu4e
e
6
eu4e
c
ms
o
:
flnpa:uuauna
-
500
rrlr
B
cnou
o
z
ame
nbHd
e
6
eu4e
cm6
a
:
Kpaxrual
rapro$enrurrfi
-
32,30
Mf,
xeJlarrau
-
Il'54
(upuruorenuf
-
l,ss
Mr,
KpeMHI{t
AI4oKcI'IA
rollouAustfi
rrlr,
xap6oxcl4Merl'InKpaxMaJl
Hurpvrfl'
(aspocran
MaPKa
A
300)
-
8,46
vr,
MafHI4q
creapar
-
3,85
rvrr.
onucanue:
Ta6lerxu
6eloro
r4rr4
lorrrlr
6eloro
IIBera
KpyI'JIbIe'
nnocKOIII'IJIHHApI',IqecKpIe
c
pucxoft
sa
oAnofi
cropoHe
co
cKoITIeHHrIMI'I
KpasMIr'
@apmarorepaneBTr{qecKas
fpynlla:
ilpoTt4BoTy6eprylesHoe
cpeAcrBo.
KOA
ATX:
J04AK01
(DapmarcoloruqecKHe
ceoft
crna
(DapmarcoduH(wuKa
flupa-:unalvltl4
-
ClIHTeTI4qecKoe
npoTl4BoTy6eprylesnoe
cpeAcTBo'
Oxagsrsaer
6axrepuocTaTllqecKo
e
vru
6arrepuquAnoe
Aeficrsue
B
3aBI'ICI4MOCTLI
oT
KOHIIeHTpaIIHI{
v
qyBcTB[TeJibHocTIt
MI,IKpoopraHH3Ma.
Bolee
aKTI'IBeH
no
ry6epxynocTaTl4qecrcofi
aKrI4BHocTIl'
qeM
IIACK,
XoTr
ycTynaeT
LI3OHI4a3LIAy,
cTpeIIToMI'IqraH],
pra(farr'rnnUuuY'
,{efic'rnyer
Ha
rr.'lxo6arrepuu,
ycroftqr,rBbre
K
ApyrI4M
,rpgt""ory6eprynesublM
Ilpeflapararrr
II
px.la'
flpenapar
xopolllo
[poHr4KaeT
B Oqar.u
ry6epryle3Horo
lopaxeHl{t.
Ero
aKTI',IBHOCTb
He
cHI4XaeTcq
B
XuC:rOfr
CpeAe
Ka3eo3HbIX
MaCC,
B
cBg3I4,
c
qeM
efg
qacTo
Ha3HaqalOT
IrpI4
Ka3eO3HbX
nrlrraQalenrarax,
ry6epKynoMax
14
Ka3eo3HO-nHeBMOHI4qecKI',IX
Ilpoqeccax'
@aptwaxoxuHemuKa
flupasuuaurrA
XOpomO
BcaCbIBaeT
cfl
v1s
Xeny,4oqHo-Kpl[IeqHoro
TpaKTa'
flocle
[pIIeMa
BHyTpb
BpocnbrM
.qosH
500
Mf,
[r{K
KOHqeHTpaIIUH
trvpa3kIHaMl{Aa
B
nJIa3Me
KpoBI4
n npe4enax
9-12
urr/ul
AOcTI,IraeTct
B
TeqeHue2qaCos,T
rv6r/
rt'rn-
qepe3
8
qaCoe
u2v1Xrlvrttqepe3
24\aca'
cpeAbl
OpfaHI43Ma,
BKJIIOllafl
IIeqeHb,
JIerKI4e
'
rtbHo
50
%
cBq3HBaercq
c
6e"IKaNau
[JIa3MbI'
)B
y
rex
IIaIII4eHToB,
$